General Information and Variability Data of DT
DT ID DTD0010
Gene Name SLC22A1
Protein Name Organic cation transporter 1
Synonyms OCT1; SLC22A1; Solute carrier family 22 member 1; hOCT1; oct1_cds
Gene ID
6580
UniProt ID
O15245
TCDB ID
2.A.1.19.29
DT Family Major Facilitator Superfamily (MFS)
Organic Cation Transporter (OCT) Family
Tissue Specificity primarily expressed on the sinusoidal (blood side) membrane of hepatocytes. OCT1 is also located on the basolateral membrane of small intestinal enterocytes, renal proximal tubular cells, and with much lower abundance in some neurons, the heart, skeletal muscle, lung, tumor cells, and basophilic granulocytes
Function This transporter translocates organic cations in an electrogenic and pH-independent manner. Translocates organic cations across the plasma membrane in both directions. Transports the polyamines spermine and spermidine. Transports pramipexole across the basolateral membrane of the proximal tubular epithelial cells. The choline transport is activated by MMTS. Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine, and metformin. The transport of organic cations is inhibited by a broad array of compounds like tetramethylammonium (TMA), cocaine, lidocaine, NMDA receptor antagonists, atropine, prazosin, cimetidine, TEA and NMN, guanidine, cimetidine, choline, procainamide, quinine, tetrabutylammonium, and tetrapentylammonium.
Disease(s) Chronic myelogenous leukemia [ICD-11: 2A20.0]
Colorectal cancer [ICD-11: 2B91]
Cytomegalovirus infections [ICD-11: 1D82]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Malaria [ICD-11: 1F40]
Ovarian cancer [ICD-11: 2C73]
Parkinson's Disease [ICD-11: 8A00.0]
Type 2 diabetes [ICD-11: 5A11]
Herpes simplex virus infection [ICD-11: 1F00]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Acebutolol Drug Info Ventricular premature beats [ICD-11: BC70] Approved [1]
Acetylcholine Drug Info Cataract [ICD-11: 9B10] Approved [2]
Acyclovir Drug Info Shingles [ICD-11: 1.00E+91] Approved [3]
Amiloride Drug Info High blood pressure [ICD-11: BA00] Approved [4]
Atenolol Drug Info High blood pressure [ICD-11: BA00] Approved [4]
Atropine Drug Info Poison intoxication [ICD-11: NE6Z] Approved [4]
Auranofin Drug Info Rheumatoid arthritis [ICD-11: FA20] Approved [5]
Buformin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [6]
Camostat Drug Info Chronic pancreatitis [ICD-11: DC32] Approved [4]
Cimetidine Drug Info Acid reflux disorder [ICD-11: DA22] Approved [4]
Cisplatin Drug Info Testicular cancer [ICD-11: 2C80] Approved [7]
Citalopram Drug Info Depression [ICD-11: 6A8Z] Approved [8]
Cladribine Drug Info Hairy cell leukemia [ICD-11: 2A82.2] Approved [6]
Clidinium Drug Info Peptic ulcer [ICD-11: DA61] Approved [4]
Clonidine Drug Info High blood pressure [ICD-11: BA00] Approved [9]
Codeine Drug Info Pain [ICD-11: MG30-MG7Z] Approved [10]
Cytarabine Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [6]
Debrisoquine Drug Info Hypertension [ICD-11: BA00] Approved [11]
Desipramine Drug Info Depression [ICD-11: 6A8Z] Approved [1]
Dinoprostone Drug Info Medical abortion [ICD-11: JA00.1] Approved [12]
Disopyramide Drug Info Ventricular arrhythmias [ICD-11: BC71] Approved [4]
Dopamine Drug Info Parkinson's Disease [ICD-11: 8A00.0] Approved [8]
Epinephrine Drug Info Asthma [ICD-11: CA23] Approved [6]
Fenoterol Drug Info Bronchospasm [ICD-11: CB40.Y] Approved [4]
Fexofenadine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [13]
Formoterol Drug Info Asthma [ICD-11: CA23] Approved [4]
Ganciclovir Drug Info Cytomegalovirus infections [ICD-11: 1D82] Approved [3]
Glycopyrrolate Drug Info Airflow obstruction of chronic obstructive pulmonary disease [ICD-11: CA22] Approved [4]
Imatinib Drug Info Gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [14]
Indacaterol Drug Info Chronic obstructive pulmonary disease [ICD-11: CA22] Approved [4]
Ipratropium Drug Info Obstructive lung diseases [ICD-11: CA22.Z] Approved [4]
Lamivudine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [15]
Lamotrigine Drug Info Epilepsy [ICD-11: 8A6Z] Approved [16]
Metformin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [17]
Metoclopramide Drug Info Vomiting [ICD-11: MD90.1] Approved [4]
Naratriptan Drug Info Migraine Headaches [ICD-11: 8A80] Approved [18]
Nizatidine Drug Info Acid reflux disorder [ICD-11: DA22] Approved [4]
Norepinephrine Drug Info Septic shock [ICD-11: 1G41] Approved [8]
Oxaliplatin Drug Info Colorectal cancer [ICD-11: 2B91] Approved [19]
Oxyphenonium Drug Info Visceral spasms [ICD-11: MD81.4] Approved [4]
Pentamidine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [20]
Perphenazine Drug Info Schizophrenia [ICD-11: 6A20] Approved [4]
Phenoxybenzamine Drug Info Malignant essential hypertension [ICD-11: BA00] Approved [1]
Pramipexole Drug Info Parkinson's Disease [ICD-11: 8A00.0] Approved [21]
Prazosin Drug Info Severe congestive heart failure [ICD-11: BD10] Approved [1]
Procainamide Drug Info Ventricular arrhythmias [ICD-11: BC71] Approved [4]
Procaterol Drug Info Asthma [ICD-11: CA23] Approved [4]
Propranolol Drug Info Migraine [ICD-11: 8A80] Approved [9]
Quinine Drug Info Malaria [ICD-11: 1F40] Approved [22]
Ranitidine Drug Info Peptic ulcer [ICD-11: DA61] Approved [23]
Rizatriptan Drug Info Migraine Headaches [ICD-11: 8A80] Approved [18]
Salbutamol Drug Info Acute asthma [ICD-11: CA23] Approved [4]
Sitagliptin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [24]
Sumatriptan Drug Info Migraine Headaches [ICD-11: 8A80] Approved [4]
Terbutaline Drug Info Asthma [ICD-11: CA23] Approved [4]
Tiotropium Drug Info Chronic obstructive pulmonary disease [ICD-11: CA22] Approved [4]
Triamterene Drug Info Edema associated with congestive heart failure [ICD-11: BD10] Approved [4]
Trimethoprim Drug Info Urinary tract infections [ICD-11: GC08] Approved [4]
Trospium chloride Drug Info Overactive bladder [ICD-11: GC50.0] Approved [25]
Tubocurarine Drug Info Smoking withdrawl syndrom [ICD-11: 6C4A.2] Approved [6]
Varenicline Drug Info Smoking cessation [ICD-11: 6C4A.2] Approved [4]
Verapamil Drug Info High blood pressure [ICD-11: BA00] Approved [1]
Zidovudine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [6]
Zolmitriptan Drug Info Migraine without aura [ICD-11: 8A80.0] Approved [18]
Clinical Trial Drug(s) Transported by This DT Berberine Drug Info Diabetes [ICD-11: 5A10-5A14] Phase 4 [26]
Choline Drug Info Elderly bronchial asthma [ICD-11: CA23] Phase 3 [6]
Tyramine Drug Info Parkinson's Disease [ICD-11: 8A00.0] Phase 3 [6]
N1-methylnicotinamide Drug Info Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 [27]
Tetraethylammonium Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Phase 2 [28]
YM155 Drug Info Non hodgkin's lymphoma [ICD-11: 2A8Z] Phase 2 [29]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT Phencyclidine Drug Info Anesthesia [ICD-11: MB40.3, MB40.8] Withdrawn [30]
Phenformin Drug Info Diabetes [ICD-11: 5A10-5A14] Withdrawn [4]
(R)-Xamoterol Drug Info Heart failure [ICD-11: BD1Z] Preclinical [4]
(S)-Xamoterol Drug Info Heart failure [ICD-11: BD1Z] Preclinical [4]
Benzamil Drug Info Cystic fibrosis [ICD-11: CA25] Preclinical [4]
N-methylpyridinium Drug Info Colon cancer [ICD-11: 2B90.Z] Preclinical [31]
Prostaglandin f2Alpha Drug Info Solid tumours [ICD-11: 2D4Z] Preclinical [32]
Spermidine Drug Info Plaque psoriasis [ICD-11: EA90.0] Preclinical [6]
Tetramethylammonium Drug Info Glaucoma [ICD-11: 9C61] Preclinical [33]
Antiparasitics Drug Info Cancer [ICD-11: 2A00-2F9Z] Terminated [20]
Endogenous Substrate(s) Primary polyamines
Endogenous Metabolites (EMs) Handled by This DT Prostaglandin E2 EM Info Identified using proximal tubule cells-OCT1h [32]
Prostaglandin F2 alpha EM Info Identified using proximal tubule cells-OCT1h [32]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Acyclovir Drug Info Proximal tubule (S2) cells-OCT1 Km = 151.2 microM [3]
Antiparasitics Drug Info Chinese hamster ovary (CHO) cells-OCT1 Km = 6.1 microM [20]
Dinoprostone Drug Info Proximal tubule (S2) cells-OCT1 Km = 0.657 microM [32]
Ganciclovir Drug Info Proximal tubule (S2) cells-OCT1 Km = 516.2 microM [3]
Ipratropium Drug Info Human embryonic kidney cells (HEK293)-OCT1 Km = 9 microM [4]
Metformin Drug Info Chinese hamster ovary (CHO) cells-OCT1 Km = 2160 microM [34]
Metformin Drug Info Human embryonic kidney cells (HEK293)-OCT1 Km = 1060 microM [35]
Metformin Drug Info Human embryonic kidney cells (HEK293)-OCT1 Km = 1470 microM [17]
Metformin Drug Info Human embryonic kidney cells (HEK293)-OCT1 Km = 5450 microM [36]
N-methylpyridinium Drug Info Madin-Darby canine kidney cells (MDCKII)-OCT1 Km = 21 microM [31]
N-methylpyridinium Drug Info Oocytes-OCT1 Km = 14.6 microM [37]
Pentamidine Drug Info Chinese hamster ovary (CHO) cells-OCT1 Km = 36.4 microM [20]
Prostaglandin f2Alpha Drug Info Proximal tubule (S2) cells-OCT1 Km = 0.477 microM [32]
Ranitidine Drug Info Oocytes-OCT1 Km = 70 microM [23]
Tetraethylammonium Drug Info Human cervical cancer cell line (Hela)-OCT1 Km = 229 microM [38]
Tetraethylammonium Drug Info Proximal tubule (S2) cells-OCT1 Km = 566 microM [28]
Trospium chloride Drug Info Primary human bladder urothelium cells (HBU) Km = 106 microM [25]
YM155 Drug Info Human embryonic kidney cells (HEK293)-OCT1 Km = 22.1 microM [29]
References
1 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
2 Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res. 2006 Apr 12;7:65.
3 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
4 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
5 Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
6 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
7 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
8 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
9 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
10 Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015 May;64(5):1786-93.
11 The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012 May 15;83(10):1427-34.
12 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
13 Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70.
14 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
15 Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008 Aug;36(8):1616-23.
16 Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012 Mar 15;83(6):805-14.
17 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
18 OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
19 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
20 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
21 OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82.
22 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
23 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
24 265 effect of dietary cholesterol on gallbladder bile lithogenicity and gene expression in the enterohepatic axis of non-obese gallstone and control women. Journal of Hepatology, 2009, 50(09):S105-S106.
25 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
26 Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008 Feb;376(6):449-61.
27 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
28 Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos. 2009 Sep;37(9):1856-63.
29 Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
30 Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011 Feb;14(1):22-34.
31 Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008 Jun;57(6):1463-9.
32 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
33 Scintillation proximity assay for measuring uptake by the human drug transporters hOCT1, hOAT3, and hOATP1B1. Anal Biochem. 2007 Jul 15;366(2):117-25.
34 Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
35 Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos. 2007 Dec;28(9):501-10.
36 Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J. 2011 Dec;11(6):400-11.
37 Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21.
38 Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.